VASCULAR-1 and VASCULAR-2 as a New Potential Angiogenesis and Endothelial Dysfunction Markers in Peripheral Arterial Disease.

Abstract

The quotient of concentrations concerning the key proangiogenic factor, that is, the vascular endothelial growth factor (VEGF-A) and the angiogenesis inhibitor, namely, its soluble receptors (sVEGFR-1 or sVEGFR-2), seems to reflect increased hypoxia and intensity of compensation angiogenesis. Therefore, it can be an ischemic and endothelial dysfunction marker reflected in intermittent claudication (IC) or critical limb ischemia (CLI) in patients with symptomatic peripheral arterial disease (PAD). The main objective of this study was to evaluate the levels of VEGF-A/sVEGFR-1 and VEGF-A/sVEGFR-2-presented using a novelty acronym VASCULAR-1 and VASCULAR-2-in patients with IC and CLI, as well as displayed in 4 classes of severity of PAD. VASCULAR-1 and VASCULAR-2 were calculated using the plasma of venous blood sampled from 80 patients with IC (n = 65) and CLI (n = 15) and the control group (n = 30). Patients with CLI were reported to have a slightly higher index of VASCULAR-1 and double VASCULAR-2 levels as compared to patients with IC (P = nonsignificant), and these markers were significantly higher than controls (P < .01 and P < .01, respectively). VASCULAR-2 levels were observed to have an increasing tendency in the subsequent degrees of PAD severity according to the Fontaine classification (P = .02). In view of the need to consider the role of the proangiogenic and antiangiogenic factor in the assessment of the so-called "angiogenic potential," VASCULAR-1 ratio and VASCULAR-2 ratio may be a new useful biomarker of limb ischemia in patients with IC and CLI. However, this requires further studies and evidence on a very large group of patients with PAD.

• Authors: Radosław Wieczór, Danuta Rość, Anna Maria Wieczór, Arleta Kulwas
• Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (Clin Appl Thromb Hemost) 2019 Jan-Dec Vol. 25 Pg. 1076029619877440 ISSN: 1938-2723 [Electronic] United States
• PMID: 31564130 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Modulating Agents
• Biomarkers
• Vascular Endothelial Growth Factor A
• Vascular Endothelial Growth Factor Receptor-1
• Vascular Endothelial Growth Factor Receptor-2

Topics

• Aged
• Angiogenesis Modulating Agents (blood)
• Biomarkers (blood)
• Endothelium (physiopathology)
• Extremities (pathology)
• Female
• Humans
• Intermittent Claudication (blood)
• Ischemia (blood)
• Male
• Middle Aged
• Peripheral Arterial Disease (blood, pathology)
• Vascular Endothelial Growth Factor A (blood)
• Vascular Endothelial Growth Factor Receptor-1 (blood)
• Vascular Endothelial Growth Factor Receptor-2 (blood)